BRIEF-Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory & Immune Diseases

Reuters02-12

Feb 12 (Reuters) - Seres Therapeutics Inc MCRB.O:

SERES PROVIDES PROGRAM AND CORPORATE UPDATES AND PRIORITIZES EMERGING PROGRAMS IN INFLAMMATORY & IMMUNE DISEASES
SERES THERAPEUTICS INC: COMPANY'S RUNWAY EXTENSION ACTIONS, INCLUDING REDUCING WORKFORCE BY APPROXIMATELY 30%
SERES THERAPEUTICS INC: EXPECTS TO EXTEND ITS CASH RUNWAY THROUGH Q3 OF 2026

Source text: ID:nGNX3kgRxF

Further company coverage: MCRB.O

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2610792565?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 20:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610792565","market":"nz","top_or_hot":-1,"title":"BRIEF-Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory & Immune Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory &amp; Immune Diseases</title></head><body><p><span>Feb 12 (Reuters)</span><span> - </span>Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>MCRB.O</span>:</p><ul><li><p>SERES PROVIDES PROGRAM AND CORPORATE UPDATES AND PRIORITIZES EMERGING PROGRAMS IN INFLAMMATORY &amp; IMMUNE DISEASES</p></li><li><p>SERES THERAPEUTICS INC: COMPANY'S RUNWAY EXTENSION ACTIONS, INCLUDING REDUCING WORKFORCE BY APPROXIMATELY 30%</p></li><li><p>SERES THERAPEUTICS INC: EXPECTS TO EXTEND ITS CASH RUNWAY THROUGH Q3 OF 2026</p></li></ul><p>Source text: <span>ID:nGNX3kgRxF</span></p><p>Further company coverage: <span>MCRB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory & Immune Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory & Immune Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-12 20:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory &amp; Immune Diseases</title></head><body><p><span>Feb 12 (Reuters)</span><span> - </span>Seres <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>MCRB.O</span>:</p><ul><li><p>SERES PROVIDES PROGRAM AND CORPORATE UPDATES AND PRIORITIZES EMERGING PROGRAMS IN INFLAMMATORY &amp; IMMUNE DISEASES</p></li><li><p>SERES THERAPEUTICS INC: COMPANY'S RUNWAY EXTENSION ACTIONS, INCLUDING REDUCING WORKFORCE BY APPROXIMATELY 30%</p></li><li><p>SERES THERAPEUTICS INC: EXPECTS TO EXTEND ITS CASH RUNWAY THROUGH Q3 OF 2026</p></li></ul><p>Source text: <span>ID:nGNX3kgRxF</span></p><p>Further company coverage: <span>MCRB.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nTUABCFYSF:1","article_id":"2610792565","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610792565","pubTimestamp":1770899209,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory & Immune DiseasesFeb 12 (Reuters) - Seres Therapeutics Inc MCRB.O:SERES PROVIDES PROGRAM AND CORPOR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MCRB":"Seres Therapeutics, Inc."},"translate_title":"简介-Seres提供项目和公司更新，并优先考虑炎症和免疫疾病中的新兴项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MCRB":0.9},"content_text":"BRIEF-Seres Provides Program And Corporate Updates And Prioritizes Emerging Programs In Inflammatory & Immune DiseasesFeb 12 (Reuters) - Seres Therapeutics Inc MCRB.O:SERES PROVIDES PROGRAM AND CORPORATE UPDATES AND PRIORITIZES EMERGING PROGRAMS IN INFLAMMATORY & IMMUNE DISEASESSERES THERAPEUTICS INC: COMPANY'S RUNWAY EXTENSION ACTIONS, INCLUDING REDUCING WORKFORCE BY APPROXIMATELY 30%SERES THERAPEUTICS INC: EXPECTS TO EXTEND ITS CASH RUNWAY THROUGH Q3 OF 2026Source text: ID:nGNX3kgRxFFurther company coverage: MCRB.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2610792565","isCrawlerRequest":true}